14:00 - 17:40
主持人 Moderator
刘颢然, 华金证券医药联席首席分析师，创新药团队负责人
Eric LIU, Co-chief Bio-pharma Analyst, Leader of Innovative Drug Research Team，Huajin Security
14:00 - 14:20
项目1
Project 1
ABP1011T和ABP1019A小分子多靶点TKI抗癌新药
Small-molecule, Multi-target TKI Anticancer Drugs: ABP1011T and ABP1019A
詹正云, 上海爱博医药科技有限公司董事长兼CEO
ZHAN Zhengyun, Chairman & CEO, Shanghai Abpharma Co., Ltd.
14:20 - 14:40
项目2
Project 2
弘合生物自研1.1类创新药KH617的进展
Development of First-in-Class Drug KH617 by Honghe Biotechnology
赵曼茜, 四川弘合生物科技有限公司总经理
ZHAO Manxi, General Manager, Sichuan Honghe Biotechnology Co., Ltd.
14:40 - 15:00
项目3
Project 3
基于活细胞化学蛋白质组学技术的新药研发及应用
Chemoproteomic Solutions for Preclinical Development of Innovative Small Molecule Drugs
侯晓萌, 南京科络思生物科技有限公司副总经理
HOU Xiaomeng, Deputy General Manager, ChomiX Biotech Co., Ltd.
15:00 - 15:20
项目4
Project 4
遗传病与出生缺陷三级防控平台
Genetic Diseases and Birth Defects Three-Level Prevention and Control Platform
高鹏飞, 上海韦翰斯生物医药科技有限公司总经理
GAO Pengfei, General Manager, Shanghai WeHealth Biomedical Technology Co., Ltd.
15:20 - 15:40
项目5
Project 5
一种新型眼科玻璃体切割平台及附件
A Novel Ophthalmic Vitrectomy Platform and Accessories
杨胜青, 江苏视界医疗器械股份有限公司总经理
YANG Shengqing, General Manager, Almic Co., Ltd.
15:40 - 16:00
项目6
Project 6
重塑免疫平衡的精准疗法
Precision Therapy for Restoring Immune Balance
邵天歌, 演生潮（北京）生物科技有限公司首席创新官
SHAO Tiange, CIO, Emergent Biomed Solutions, Ltd.,
16:00 - 16:20
项目7
Project 7
新型IBD治疗药物：全新GPCRx的口服小分子激动剂
Novel IBD Therapeutic Drug: A New Oral Small-Molecule Agonist of GPCRx
刘峰, 博迪贺康（北京）生物技术有限公司首席运营官
Tony LIU, Chief Operating Officer, Benethera Biotechnology Co., Ltd.
16:20 - 16:40
项目8
Project 8
晚期HR+/HER2-乳腺癌患者的治疗新选择——小分子口服Pan-Akt抑制剂NTQ1062片的研究进展
Novel Therapeutic Option for Patients with Advanced HR+/HER2- Breast Cancer: Research Advances in the Small-Molecule Oral Pan-Akt Inhibitor NTQ1062 tablet
季晓君, 南京正大天晴制药有限公司转化医学负责人
JI Xiaojun, Head of Translational Medicine, Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd.
16:40 - 17:00
项目9
Project 9
一款PK优异、药效显著的潜在BIC泛RAS(ON)抑制剂
A Potential Best-in-Class pan-RAS(ON) Inhibitor with Outstanding Oral PK and In vivo Efficacy Data
王淑祥, 荣昌制药股份有限公司BD总监
WANG Shuxiang, BD Director, Rongchang Pharmaceuticals Co., Ltd.
17:00 - 17:20
项目10
Project 10
四价重组诺如病毒疫苗（汉逊酵母）
Quadrivalent Recombinant Norovirus Vaccine (Hansenula yeast)
张红霞, 华北制药金坦生物技术股份有限公司总经理助理
ZHANG Hongxia, Assistant to the General Manager, NCPC GeneTech Biotechnology Development Company Limited
17:20 - 17:40
项目11
Project 11
博骥源：聚焦代谢和炎症性疾病的小分子创新药平台
Burgeon：A Small-Molecule Innovative Drug Platform Focused on Metabolic and Inflammatory Diseases
王超略, 博骥源（上海）生物医药有限公司融资负责人
Charles WANG, Investment Director，Burgeon Therapeutics Co., Ltd.
会议咨询